Sanofi (NYSE:SNY) Stake Decreased by Keystone Financial Planning Inc.
Keystone Financial Planning Inc. decreased its stake in Sanofi (NYSE:SNY) by 1.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,277 shares of the company’s stock after selling 610 shares during the period. Keystone Financial Planning Inc.’s holdings in Sanofi were worth $1,978,000 as of its most recent filing with the SEC.
Several other large investors have also recently added to or reduced their stakes in SNY. Guggenheim Capital LLC boosted its stake in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the period. Capstone Asset Management Co. boosted its stake in Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock valued at $3,719,000 after buying an additional 4,635 shares during the period. Atria Investments LLC boosted its stake in Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock valued at $334,000 after buying an additional 602 shares during the period. BLB&B Advisors LLC purchased a new stake in Sanofi during the first quarter valued at about $202,000. Finally, Cullinan Associates Inc. boosted its stake in Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the period. 9.96% of the stock is owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE SNY) opened at 47.55 on Friday. The firm has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88. The company’s 50-day moving average is $47.99 and its 200 day moving average is $46.11. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. Analysts anticipate that Sanofi will post $3.26 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/sanofi-nysesny-stake-decreased-by-keystone-financial-planning-inc/1478351.html.
SNY has been the subject of several recent analyst reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Zacks Investment Research cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, BidaskClub cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.